Embla Medical hfOSSFF 92 Debt-to-EBITDA is 3.49 as of Mar. 2026, which is 20% above its 10-year median of 2.91. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.33. The stock has 2 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Embla Medical hf ranks worse than 68.16% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Embla Medical hf's Debt-to-EBITDA or its related term are showing as below:
OSSFF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.66 Med: 2.91 Max: 5.55
Current: 2.87
During the past 13 years, the highest Debt-to-EBITDA Ratio of Embla Medical hf was 5.55. The lowest was 1.66. And the median was 2.91.
OSSFF's Debt-to-EBITDA is ranked worse than 68.16% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs OSSFF: 2.87
Embla Medical hf (OTCPK:OSSFF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Embla Medical hf Debt-to-EBITDA Related Terms
Embla Medical hf Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Embla Medical hf's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Embla Medical hf (OSSFF) has a Debt-to-EBITDA of 3.49 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Embla Medical hf. This is 20% above median its historical median of 2.91. Over the past decade, Embla Medical hf's Debt-to-EBITDA has ranged from 1.66 to 5.55. According to the industry distribution chart, Embla Medical hf ranks #319 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 68.2%.
Is Embla Medical hf's Debt-to-EBITDA too high?
Embla Medical hf's current Debt-to-EBITDA of 3.49 is 20% above median its 10-year median of 2.91. Over the past 10 years, this metric has ranged from a low of 1.66 to a high of 5.55. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. Embla Medical hf's value of 3.49 is 124.4% above this industry median. Based on the distribution chart, Embla Medical hf ranks #319 out of 468 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #319 out of 468 companies for Debt-to-EBITDA. This places Embla Medical hf in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. Embla Medical hf's value of 3.49 is 124.4% above this benchmark. Historically, Embla Medical hf's own Debt-to-EBITDA has ranged from 1.66 to 5.55 over the past decade. While the company's 10-year median is 2.91 vs. the industry median of 1.56, Embla Medical hf has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current Debt-to-EBITDA of 3.49 is 124.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Embla Medical hf. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current Debt-to-EBITDA is 3.49, which is 20% above median its own 10-year median of 2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current Debt-to-EBITDA of 3.49. The stock's GF Value™ is $5.33, compared to a current price of $4.15 — trading 22.1% below its estimated fair value. The current Debt-to-EBITDA is 3.49, which is 20% above median its 10-year median of 2.91 and 124.4% above the Medical Devices & Instruments industry median of 1.56. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current Debt-to-EBITDA is 3.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 22.1% below its estimated GF Value™ of $5.33.
Key valuation signals for OSSFF:
Debt-to-EBITDA: 3.49 (20% above median its 10-year median of 2.91)
GF Value™: $5.33 vs. price of $4.15 (22.1% below fair value)
Industry Position: 124.4% above the Medical Devices & Instruments median (#319 of 468)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
